NeuroSense Therapeutics
NRSN
13 hedge funds and large institutions have $266K invested in NeuroSense Therapeutics in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
30% more funds holding
Funds holding: 10 → 13 (+3)
0.06% more ownership
Funds ownership: 1.11% → 1.17% (+0.06%)
23% less capital invested
Capital invested by funds: $347K → $266K (-$80.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YAG
Yorkville Advisors Global
Mountainside,
New Jersey
|
+$105K |
| 2 |
GS
GTS Securities
Miami,
Florida
|
+$37.7K |
| 3 |
Two Sigma Investments
New York
|
+$32.1K |
| 4 |
Pathstone Holdings
Englewood,
New Jersey
|
+$17.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$17.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$83K |
| 2 |
Squarepoint
New York
|
-$81.6K |
| 3 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
-$1K |
NRSN Hedge Fund Activity: Q4 2025 in Review
13 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q4 2025, worth a combined $266K — down 23% from $347K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NRSN positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Yorkville Advisors Global, opening a new position worth an estimated $105K. The largest seller was Morgan Stanley, exiting entirely with an estimated $83K sold.
- 13 institutional investors held NeuroSense Therapeutics (NRSN) as of Q4 2025, up from 10 in Q3 2025.
- Funds reported $266K of NeuroSense Therapeutics stock for Q4 2025, down 23% quarter-over-quarter.
- 5 funds opened new NeuroSense Therapeutics positions in Q4 2025 and 2 closed out, a net change of +3 holders.
- The largest NeuroSense Therapeutics buyer in Q4 2025 was Yorkville Advisors Global, an estimated $105K added.
- The largest NeuroSense Therapeutics seller in Q4 2025 was Morgan Stanley, an estimated $83K sold.
Based on aggregated 13F filings for Q4 2025.